By Fineline Cube 
The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of excessive drug prescribing. The directive sets a phased timeline for nationwide coverage, mandates inclusion of high‑risk pharmacy items, and frames the analytical rules around three drug categories and behavior patterns.
Timeline & Coverage Milestones
| Deadline | Scope | Objective |
|---|---|---|
| Dec 2025 | 50 key monitored medical‑insurance drugs in pilot regions | Establish initial intelligent‑monitoring framework |
| Jun 2026 | 100 key monitored drugs nationwide | Expand provincial coverage |
| Dec 2026 | Full coverage of all key drugs | Institute uniform national rules and seamless data‑integration across screening, alerts, and enforcement |
Drug Categories Under Focus
- Financially aberrant drugs – those linked to illegal or irregular claims.
- Cost‑driven drugs – top‑payer items from the pooling fund with abnormal expenditure curves.
- High‑margin resale drugs – popular items with substantial resale appeal and profit spreads.
Abnormal Purchasing Behaviors
- Excessive volume – prescriptions that markedly exceed the clinically reasonable scope for a period.
- Cross‑institution repetition – same drug repeatedly prescribed across multiple institutions without a change in clinical status.
- Anomalous timing or identity – frequent buys in short intervals or use of another person’s name.
Targeted Institutions & Personnel
- Suspected insured individuals attempting to profiteer from medical‑insurance drug benefits.
- Designated prescriber clusters – departments where over‑prescribing is concentrated.
- Medical staff implicated in orchestrating or facilitating non‑compliant prescribing practices.-Fineline Info & Tech